Alrise Biosystems, a Berlin, Germany-based drug-delivery company focused on nano- and micro-encapsulation technology, has entered into an agreement with exclusive option rights with Ferring Pharmaceuticals, a Parsippany, New Jersey-based privately-held biopharmaceutical company, for the development of an injectable, controlled-release formulation of a peptide therapeutic using Alrise’s proprietary ImSus technology platform.

Under the agreement, Alrise will conduct feasibility and scale-up studies with Ferring, and, upon completion of the development work, Ferring will have the right to exercise its option and enter into a definitive agreement with Alrise to further develop and manufacture the formulation.

Alrise’s proprietary ImSus technology platform allows for the manufacture of drug-loaded polymeric microparticles based on the encapsulation of both hydrophilic and hydrophobic drugs independent of the molecule size, which facilitates controlled-release formulations. The technology is compatible with both biodegradable and non-biodegradable polymers commonly used for drug delivery applications, including controlled-release parenteral and oral administration.

Source: Alrise Biosystems